INTRODUCTION
Recent advances in personalized medicine in non-small cell lung cancer (NSCLC) have dramatically shifted the paradigm of lung cancer treatment, in particular for patients with stage IV tumors. Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors have been implemented as standard, first-line therapy for patients with advanced NSCLC whose tumors harbor the corresponding mutations, 1 and a c-ros oncogene 1, receptor tyrosine kinase (ROS1) inhibitor, crizotinib, was added to the list in March 2016. 2 Although tyrosine kinase inhibitors have led to significantly improved progression-free survival, 3 the majority of patients eventually develop resistance to genotype-specific therapies. In addition, a significant percentage of patients with NSCLC do not have genetic alterations that currently are targetable with therapies that have been approved by the US Food and Drug Administration (FDA). 4 More recently, the blockade of immune checkpoints to reinstitute host antitumor immunity has been investigated extensively. 5 Immune checkpoint molecules refer to a group of immune receptors that, when engaged with their ligands, transmit an inhibitory signal to suppress effector function, and the inhibitory pathways can be used by cancer to evade tumor immunity. 5 Thus, the blockade of immune checkpoints may be effective in a variety of tumors that are refractory to other therapies. Of those, monoclonal antibodies targeting the programmed cell death protein 1 (PD-1, also known as CD279) receptor and its ligand, programmed death-ligand 1 (PD-L1, also known as B7-H1) have been studied extensively in the field of lung cancer. In high-profile clinical trials, anti-PD-1 and PD-L1 agents have demonstrated impressive antitumor activity in patients with NSCLC, [6] [7] [8] and significant improvements were noted with regard to overall survival among previously treated patients with advanced NSCLC compared with single-agent docetaxel. [9] [10] [11] [12] These results have led to FDA approval of nivolumab, pembrolizaumab, and atezolizumab for patients with NSCLC who experience disease progression during or after platinum-based chemotherapy. 13 Durvalumab has received a fast-track status for the treatment of patients with advanced NSCLC who experience disease progression after 2 lines of therapy and PD-L1 expression. Furthermore, the results of the KEYNOTE-024 clinical trial have shown a significantly improved objective response rate, progression-free survival, and overall survival when patients with advanced NSCLC whose tumors were found to harbor PD-L1 expression by immunohistochemistry (IHC) in 50% of the tumor cells were treated with pembrolizumab compared with platinum-based chemotherapy in the first-line setting. 14 Subsequently, pembrolizu-It is interesting to note that 5 different PD-L1 IHC assays have been developed for the 5 PD-1/PD-L1 agents, and PD-L1 expression in the tumor by the specific IHC assay has served as a predictive biomarker in those clinical trials (Table 1) . Therefore, PD-L1 IHC assays also were approved by the FDA as either companion (a requirement for drug eligibility) or complementary (only for guidance) diagnostic kits along with the corresponding anti-PD-1/ PD-L1 agents. Since pembrolizumab became available as a first-line therapy, the paradigm of treatment for patients with advanced NSCLC again has shifted (Fig. 1) . This paradigm shift has been reflected in the National Comprehensive Cancer Network guidelines that payers usually refer to. They recommend that all samples of advanced NSCLC be tested with a PD-L1 IHC assay in a reflex manner 2 ; however, these guidelines do not specify which PD-L1 assay should be used. Thus, each pathology laboratory needs to select and validate its own assay(s) from multiple PD-L1 IHC assays (clinical trial assays and laboratory-developed tests [LDTs] ).
PD-L1 IHC Assays and Scoring
As briefly mentioned in the previous section (Table 1) . Although each of the 5 IHC assays recognizes PD-L1 protein, the manner in which individual anti-PD-L1 antibody clones were developed (using hybridomas) is different, and therefore each antibody clone will be specific for a different epitope of the PD-L1 protein and may not have the same binding affinity for its epitope. In addition, different assays will use different detection chemistry, with or without amplification, to generate the color stain (chromogen) on the slide. Therefore, these 5 assays are not the same, and their performance may be different.
The availability of up to 5 different drug-assay combinations for a given indication in NSCLC has brought unique challenges to the pathology and oncology communities. To the best of my knowledge, the outcomes for patients when using these drugs in a cohort selected for "positive" PD-L1 expression have been validated only in trials using the specific drug-assay combinations (Table 1) . Furthermore, scoring guidelines to determine "positive" results are quite different between the 5 assays. These guidelines were determined based on a predictive value and clinical data obtained during the therapeutic/diagnostic test codevelopment process of individual anti-PD-1/PD-L1 agents, resulting in individual PD-L1 diagnostic guidelines that are uniquely tailored for each agent. For example, complete circumferential or partial linear membranous staining of tumor cells irrespective of intensity with or without cytoplasmic staining is considered positive for the Dako 22C3, 28-8, and 73-10 assays, whereas any membranous and/or cytoplasmic expression of tumor cells is considered positive for the Ventana SP263 assay. For the Ventana SP143 assay, tumor cell expression as well as immune cell expression are taken into account. In addition, each assay has a specific percentage of positive tumor cells as a cutoff value, and the figure may be different depending on the first-line versus second or more lines of treatment. Recently, the Ventana SP263 assay was approved in Europe for the identification of patients with nonsquamous NSCLC who are most likely to benefit from nivolumab. 15 It is interesting to note that the scoring criteria for the Dako 28-8 assay are applied when evaluating PD-L1 expression by the Ventana SP263 assay for nivolumab therapy, whereas the default criteria (25% of tumor cells positive for membranous and/or cytoplasmic staining) are used for durvalumab.
Harmonization of PD-L1 IHC Testing
Operating 5 different PD-L1 IHC assays to support the use of 5 drugs is extremely challenging in any institution not only because of the availability of various IHC platforms (automation), the significantly expensive operational costs (antibodies and reagents), and the complexity of conducting and interpreting multiple tests for this same PD-L1 protein, but also because of the limited availability of tumor tissue for testing and the number of tissue-based diagnostic tests required in the management of a patient with advanced NSCLC. Thus, it is reasonable to consider whether we can use only one of these assays or any other LDT assay to select patients for anti-PD-1/PD-L1 therapy, in particular in the reflex setting. To respond to this question, although only from the technical/analytical perspective, several studies have compared the performance of clinical trial PD-L1 IHC assays. [16] [17] [18] The International Association for the Study of Lung Cancer and the American Association for Cancer Research, in collaboration with pharmaceutical companies and diagnostics venders, have evaluated the technical similarities and differences (not the predictive equivalency) of 4 of the PD-L1 IHC assays (Dako 28-8, Dako 22C3, Ventana SP263, and Ventana SP142 assays). 18 The initial phase 1 part of this study was to test the feasibility on a small cohort of 38 NSCLC 
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Cancer Cytopathology Finally, a study with 493 NSCLC tissue samples stained using 3 assays (Dako 28-8, Dako 22C3, and Ventana SP263 assays) scored by a single trained pathologist reported similar patterns of tumor membranous staining, with a high (>90%) overall percentage agreement between the assays at multiple expression cutoff values (including 1%, 10%, 25%, and 50%). 16 It appears that the Dako 22C3, Dako 22-8, and Ventana SP263 assays could potentially be used interchangeably to identify those patients most likely to respond to anti-PD-1/PD-L1 agents (nivolumab, pembrolizumab, and durvalumab) provided that the appropriate scoring guidelines are used for the corresponding agent. 16 Conversely, the Ventana SP142 assay, which consistently demonstrated fewer numbers of positive tumor cells and includes the immune cell component for scoring, may not be interchangeable with the other assays.
What about LDTs? LDTs could be developed using either clinical trial antibody clones or nonclinical trial clones. Recently, Neuman et al reported successful implementation of the Dako 22C3 assay IHC on the Ventana BenchMark XT platform with 2 of Ventana's detection systems after a rigorous optimization process. 19 Among multiple, nonclinical trial PD-L1 antibody clones commercially available, the E1L3N (CST) clone has been optimized with various IHC platforms and detection systems, and has been used in multiple clinical studies. 17, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] In addition, a prospective, multi-institutional assessment for 4 PD-L1 IHC assays has shown the possible usefulness of E1L3N IHC on the Leica BOND platform (Leica Biosystems Inc, Buffalo Grove, Ill). 31 The study, sponsored by the National Comprehensive Cancer Network and BristolMyers Squibb, involved 13 pathologists who scored 90 surgically resected NSCLC specimens that were stained using the Dako 22-8, Dako 22C3, Ventana SP142, and E1L3N/Leica assays. Again, the Ventana SP142 assay was found to demonstrate significantly less expression by a large amount with every method of assessment (individual and average). Using the average pathologist scores across all 90 cases, only the Dako 28-8 and E1L3N/Leica assays were not found to be statistically significantly different from each other, and the Dako 22C3 assay demonstrated significantly less expression than the other 2 antibodies (only when averaging the readings of 13 pathologists), but there was no difference noted with regard to sensitivity and specificity equivalents between the Dako 22-8, Dako 22C3, and E1L3N/Leica assays using a "real-world" assessment (agreement by individual pathologists). 31 The results of these studies have brought optimism that harmonization between assays, including LDTs, may be possible. On a somber note, the recent French study comparing the performance of clinical trial assays and various combinations of LDTs reported that only 50% of LDTs were found to demonstrate sufficient concordance with the reference assays for tumor cell staining. 32 The study consisted of 41 32 Thus, not all LDTs will behave in the same way as the clinical trial assays.
It is important to note that the successful implementation of IHC-based assays in general also depends on preanalytic tissue handling 33 as well as the antigen retrieval and detection systems. An ischemia time from excision to the initiation of formalin fixation should be short (as short as possible), and biopsies should be immersed in neutral buffered formalin for 6 to 48 hours. It is important to note that the PD-L1 IHC assays have not been validated for decalcified tissues, 34, 35 and thus PD-L1 IHC on decalcified tissues should be avoided when another tissue sample is available. Specimen age for PD-L1 testing should be <3 years because concordance on PD-L1 expression with recently procured samples is high for archival samples <3 years old, but it drops significantly for those aged >3 years. 36 In addition, in our experience, the antigen retrieval conditions (citrate buffer of pH 6 vs citrate buffer of pH 8 or ethylenediaminetetraacetic acid [EDTA] of pH 9) have been shown to significantly affect the intensity and rate of positivity for the E1L3N clone (unpublished observation) (Fig. 2 ). These differences may alter the outcome of the test, leading to alternative PD-L1 scoring around a given cutoff threshold. Another challenge associated with LDTs is the lack of oversight and insufficient standardization when they are used for predictive biomarker testing in oncology practice. In the United States, the College of American Pathologists has developed a set of recommendations and expert consensus opinions regarding the validation of IHC LDTs. Although it recommends the examination of 20 positive and 20 negative samples for predictive biomarkers, 37 the various definitions of positive and negative PD-L1 staining by several anti-PD-1/PD-L1 agents may also complicate this validation process for individual laboratories. Within this context, multiple cutoff comparisons using a spectrum of samples may overcome the issue, but it will result in a major validation process for any laboratory that opts to use an LDT. Alternatively, an LDT could be validated through a head-to-head comparison of PD-L1 expression levels with a clinical trial PD-L1 IHC assay by multiple observers, using an adequate number of positive and negative samples and/ or tissue microarrays. Due to the current lack of any clinical outcome data using anything other than a clinical trial assay, to the best of my knowledge the only reference that can be used to validate a LDT within this context would be a clinical trial assay, and given the approval of pembrolizumab as a first-line therapy for patients with advanced NSCLC, the Dako 22C3 assay may serve as the best reference for now.
Cytological Application of PD-L1 IHC Testing
All PD-L1 IHC assays are intended for the detection of the PD-L1 protein in formalin-fixed, paraffin-embedded tissue. Although at least 30% to 40% of cases of advanced NSCLC are diagnosed by cytology alone, the use of cytology samples for PD-L1 IHC currently is not recommended because none of the assays has been validated for this purpose. 35 The study by Rebelatto et al also has shown that 95% alcohol; acidified formal alcohol (AFA); and 
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PREFER fixative (Anatech Ltd, Battle Creek, Mich) are unacceptable fixatives for use with the SP263 clone, whereas zinc formalin and Z-5 fixative (Anatech Ltd) in addition to neutral buffered formalin are acceptable. 38 Furthermore, an evaluation of PD-L1-positive immune cells with the Ventana SP142 assay will likely be more challenging in cytology specimens because the lack of tissue architecture precludes distinction of the relevant immune cells within the tumor area from immune cells outside of the tumor boundaries that are considered irrelevant for PD-L1 scoring. Preexisting lymphocytes in a fine-needle aspirate of a lymph node also preclude optimal immune cell scoring. However, when a cytology specimen is the only one available, a cell block may be used for PD-L1 testing provided it is made following an appropriate protocol and contains a sufficient number of tumor cells (minimum, 50-100 tumor cells) (Fig. 3) . In studies published in abstract form, Russell-Goldman et al and Skov et al demonstrated high concordance on PD-L1 expression between cell blocks and matched histological specimens, suggesting that cytological material is as good as histological material for PD-L1 IHC tumor cell analysis. 39, 40 Similarly, Heymann et al have shown comparable PD-L1 expression among cell blocks, small biopsies, and surgical resection specimens in a prospective cohort of 200 NSCLC samples. Of those, >1 sample was obtained in 15 cases, and all of them revealed concordant PD-L1 expression between the samples. 41 However, it is important to note that PD-L1 IHC on cell blocks may require modification of standard PD-L1 interpretation criteria given that cytoplasmic and globular staining patterns may need to be considered as positive regardless of cytologic sample media/fixatives and processing methods. 42 Thus, large-scale validation studies are warranted to establish PD-L1 IHC testing on cytology specimens.
Conclusions
Given the recent FDA approval of an anti-PD-1 agent as a first-line therapy for patients with advanced NSCLC, PD-L1 IHC testing has become routine in pathology laboratories in the United States. However, the concept of "1 drug, 1 predictive biomarker" has brought unique challenges to the pathology and oncology communities because operating 5 different PD-L1 IHC assays to support the use of 5 drugs is extremely difficult in any institution from both a practical and financial perspective. Thus, harmonization of PD-L1 IHC assays is highly warranted. The recent studies evaluating and comparing the analytical/technical performance of clinical trial assays and/or LDTs have shown optimism that the harmonization may be feasible, although they emphasize the importance of rigorous optimization and validation processes for LDTs that are used to identify patients who will likely respond to anti-PD-1/PD-L1 agents. In addition, similar to other IHC protocols, appropriate preanalytical tissue handling and the selection of optimal tissue samples are key to successful PD-L1 IHC. In this context, cytology smears and cell blocks are currently not recommended for use with PD-L1 IHC assays, but cell blocks that are made following appropriate protocols may be used with caution.
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